TABLE OF CONTENTS
|
|
July 2008 Volume 26, Issue 7 |
 |
|
|
 |
 In This Issue
Editorials
News
Bioentrepreneur
Opinion and Comment
Features
News and Views
 Research
Corrigenda
Errata
Naturejobs
|
|
|
|
 |
The Source Event – London, 26/09/2008
The Source Event is a dedicated science career fair from Naturejobs. Meet 1-1 with employers from across Europe looking to fill hundreds of vacancies. REGISTER NOW for the conference and workshop sessions.
Post your career questions for The Source Event speakers before the event - join the online discussion forum on Nature Network.
|
|
|
|
|
|
|
|
| |
| Advertisement |
|
 SciBX: Science-Business eXchange:
- Saves you time and resources by identifying and describing key translational research.
- Provides scientific and commercial perspectives on the key papers.
- Identifies novel competition.
- Facilitates early opportunities for investment, alliances and partnerships.
Subscribe today at www.scibx.com |
|
|
| |
|
| |
In This Issue |
 Top |
|
 |
|
| PDF |
|
Editorials |
Top |
|
|
|
|
The other path for follow-ons p715
doi:10.1038/nbt0708-715
With follow-on biologics essentially dead in the water in the US, the decision of the world's largest generics manufacturer to invest in a platform for enhancing protein pharmacokinetics could pay dividends.
Full Text | PDF
|
|
|
|
|
In need of counseling? p716
doi:10.1038/nbt0708-716
Moves to clamp down on companies offering direct-to-consumer genetic tests are out of step with personal genomics and its potential to empower individuals' role in their own healthcare.
Full Text | PDF
|
|
News |
Top |
|
|
|
|
€2 billion IMI launched with European pharma pp717 - 718
John Hodgson
doi:10.1038/nbt0708-717
Full Text | PDF
|
|
|
|
|
Dyax backs albumin p718
Mark Ratner
doi:10.1038/nbt0708-718
Full Text | PDF
|
|
|
|
|
Commercial interest waxes for IGF-1 blockers pp719 - 720
Randy Osborne
doi:10.1038/nbt0708-719
Full Text | PDF
|
|
|
|
|
Meta-analysis torpedoes blood substitutes pp721 - 723
Charlie Schmidt
doi:10.1038/nbt0708-721a
Full Text | PDF
|
|
|
|
|
UK passes hybrids p721
Nuala Moran
doi:10.1038/nbt0708-721b
Full Text | PDF
|
|
|
|
|
Tighter gene tests p721
Jeff Fox
doi:10.1038/nbt0708-721c
Full Text | PDF
|
|
|
|
|
Biofuels, take two p722
Emily Waltz
doi:10.1038/nbt0708-722a
Full Text | PDF
|
|
|
|
|
50 cancers to be sequenced p722
Henry Nicholls
doi:10.1038/nbt0708-722b
Full Text | PDF
|
|
|
|
|
Pfizer jettisons Esperion pp724 - 725
Catherine Shaffer
doi:10.1038/nbt0708-724
Full Text | PDF
|
|
|
|
|
Genetically modified mosquitoes p725
Susan Aldridge
doi:10.1038/nbt0708-725a
Full Text | PDF
|
|
|
|
|
Pan-EU Biobanks p725
Barbara Nasto
doi:10.1038/nbt0708-725b
Full Text | PDF
|
|
|
|
|
Profile: Julian Davies p727
George S. Mack
doi:10.1038/nbt0708-727
An icon of the European biotech industry and a pioneer of metagenomics, Julian Davies continues to pursue his lifelong love affair with microbiology.
Full Text | PDF
|
|
|
|
| Data Page |
|
|
|
|
State of the biotech sector[mdash]2007 p728
Stacy Lawrence
doi:10.1038/nbt0708-728
Full Text | PDF
|
|
|
|
| News Feature |
|
|
|
|
Poised to branch out pp729 - 732
Vivien Marx
doi:10.1038/nbt0708-729
Although dendrimers have not yet taken the drug industry by storm, biomedical research and industrial applications of these tiny, highly branched molecules continue to grow. Vivien Marx reports.
Full Text | PDF
|
|
Bioentrepreneur |
Top |
|
|
|
| Building a business |
|
|
|
|
Preparing for (and avoiding) the courtroom pp733 - 735
Jeff Wolfson and Russ Emerson
doi:10.1038/bioe.2008.6
PDF
|
|
Opinion and Comment |
Top |
|
|
|
| Correspondence |
|
|
|
|
Europe to ban direct-to-consumer genetic tests? pp736 - 737
Pascal Borry
doi:10.1038/nbt0708-736
Full Text | PDF
|
|
|
|
|
Dichotomies between computational and mathematical models pp737 - 738
C Anthony Hunt, Glen E P Ropella, Sunwoo Park and Jesse Engelberg
doi:10.1038/nbt0708-737
Full Text | PDF
|
|
|
|
|
Reply to Dichotomies between computational and mathematical models pp738 - 739
doi:10.1038/nbt0708-738
Full Text | PDF
|
|
|
|
|
HLA-haplotype banking and iPS cells pp739 - 740
Norio Nakatsuji, Fumiaki Nakajima and Katsushi Tokunaga
doi:10.1038/nbt0708-739
Full Text | PDF
|
|
|
|
|
Global mRNA changes in microarray experiments pp741 - 742
Matthew A Hannah, Henning Redestig, Andrea Leisse and Lothar Willmitzer
doi:10.1038/nbt0708-741
Full Text | PDF
|
|
|
|
| Commentary |
|
|
|
|
(Re)defining biopharmaceutical pp743 - 751
Ronald A Rader
doi:10.1038/nbt0708-743
Vested interests are redefining, rebranding and co-opting what is 'biopharmaceutical'. This is not just a matter of semantics[mdash]the core identity of the biotech industry and its products is at stake.
Full Text | PDF
|
|
Features |
Top |
|
|
|
|
Public biotech 2007[mdash]the numbers pp753 - 762
Stacy Lawrence and Riku Lahteenmaki
doi:10.1038/nbt0708-753
Record profits and financing in the public biotech sector may be unsustainable in the coming years as economies falter.
Full Text | PDF
|
|
|
|
| Patents |
|
|
|
|
How many patents does a biopharmaceutical company need? pp763 - 766
Deepak Kumar Parida, Ritu Mehdiratta and Gayatri Saberwal
doi:10.1038/nbt0708-763
Young biotech companies may not need extensive patent portfolios to survive or grow.
Full Text | PDF
|
|
|
|
|
Recent patent applications in mass spectrometry p767
doi:10.1038/nbt0708-767
Full Text | PDF
|
|
News and Views |
Top |
|
|
|
|
|
|
|
|
Research |
Top |
|
|
|
| Analysis |
|
|
|
|
A Bayesian deconvolution strategy for immunoprecipitation-based DNA methylome analysis pp779 - 785
Thomas A Down, Vardhman K Rakyan, Daniel J Turner, Paul Flicek, Heng Li, Eugene Kulesha, Stefan Graf, Nathan Johnson, Javier Herrero, Eleni M Tomazou, Natalie P Thorne, Liselotte Backdahl, Marlis Herberth, Kevin L Howe, David K Jackson, Marcos M Miretti, John C Marioni, Ewan Birney, Tim J P Hubbard, Richard Durbin, Simon Tavare and Stephan Beck
doi:10.1038/nbt1414
An inability to estimate absolute DNA methylation levels has slowed progress in understanding the role of this epigenetic modification in health and disease. Down et al. describe an algorithm for analyzing methylated DNA immunoprecipitation profiles generated using either high-throughput sequencing or oligonucleotide arrays.
Abstract | Full Text | PDF
|
|
|
|
| Perspective |
|
|
|
|
Refinement and standardization of synthetic biological parts and devices pp787 - 793
Barry Canton, Anna Labno and Drew Endy
doi:10.1038/nbt1413
Abstract | Full Text | PDF
See also: News and Views by Arkin
|
|
|
|
| Brief Communications |
|
|
|
|
Induction of pluripotent stem cells by defined factors is greatly improved by small-molecule compounds pp795 - 797
Danwei Huangfu, Rene Maehr, Wenjun Guo, Astrid Eijkelenboom, Melinda Snitow, Alice E Chen and Douglas A Melton
doi:10.1038/nbt1418
Existing methods for reprogramming somatic cells to 'induced pluripotent stem cells' are inefficient, with only a small fraction of the starting cell population becoming pluripotent. Working with mouse embryonic fibroblasts, Hunagfu et al. increase reprogramming efficiency by treatment with DNA methyltransferase and histone deacetylase inhibitors.
First paragraph | Full Text | PDF
|
|
|
|
| Articles |
|
|
|
|
An orally delivered small-molecule formulation with antiangiogenic and anticancer activity pp799 - 807
Ofra Benny, Ofer Fainaru, Avner Adini, Flavia Cassiola, Lauren Bazinet, Irit Adini, Elke Pravda, Yaakov Nahmias, Samir Koirala, Gabriel Corfas, Robert J D'Amato and Judah Folkman
doi:10.1038/nbt1415
Widespread use of antiangiogenic drugs for cancer therapy is limited in part by the requirement for intravenous injection. Benny et al. describe an oral formulation of an antiangiogenic small molecule that inhibits tumor growth and prevents liver metastases in mice.
Abstract | Full Text | PDF
See also: News and Views by James et al.
|
|
|
|
|
Establishment of HIV-1 resistance in CD4+ T cells by genome editing using zinc-finger nucleases pp808 - 816
Elena E Perez, Jianbin Wang, Jeffrey C Miller, Yann Jouvenot, Kenneth A Kim, Olga Liu, Nathaniel Wang, Gary Lee, Victor V Bartsevich, Ya-Li Lee, Dmitry Y Guschin, Igor Rupniewski, Adam J Waite, Carmine Carpenito, Richard G Carroll, Jordan S Orange, Fyodor D Urnov, Edward J Rebar, Dale Ando, Philip D Gregory, James L Riley, Michael C Holmes and Carl H June
doi:10.1038/nbt1410
Abstract | Full Text | PDF
|
|
|
|
|
Treatment of arthritis with a selective inhibitor of c-Fos/activator protein-1 pp817 - 823
Yukihiko Aikawa, Kimiko Morimoto, Tetsuya Yamamoto, Hisaaki Chaki, Akira Hashiramoto, Hirokazu Narita, Shuichi Hirono and Shunichi Shiozawa
doi:10.1038/nbt1412
Therapies that target only one inflammatory cytokine such as tumor necrosis factor [alpha] are often insufficient to treat rheumatoid arthritis. Aikawa et al. show that a small molecule targeting c-Fos/AP-1, a transcription factor that regulates both inflammatory cytokines and matrix metalloproteinases, inhibits type II collagen-induced arthritis in mice.
Abstract | Full Text | PDF
|
|
|
|
| Letter |
|
|
|
|
Electrostatic readout of DNA microarrays with charged microspheres pp825 - 830
Nathan G Clack, Khalid Salaita and Jay T Groves
doi:10.1038/nbt1416
Microarray platforms usually rely on fluorescence detection. Clack et al. present an equally sensitive, label-free technique that electrostatically detects DNA or RNA hybridization after randomly dispersing charged microspheres onto the microarray surface.
First paragraph | Full Text | PDF
|
|
Corrigenda |
Top |
|
|
|
|
Corrigendum: Large-scale chemical dissection of mitochondrial function p831
Bridget K Wagner, Toshimori Kitami, Tamara J Gilbert, David Peck, Arvind Ramanathan, Stuart L Schreiber, Todd R Golub and Vamsi K Mootha
doi:10.1038/nbt0708-831a
Full Text | PDF
|
|
|
|
|
Corrigendum: Isolation and directed differentiation of neural crest stem cells derived from human embryonic stem cells p831
Gabsang Lee, Hyesoo Kim, Yechiel Elkabetz, George Al Shamy, Georgia Panagiotakos, Tiziano Barberi, Viviane Tabar and Lorenz Studer
doi:10.1038/nbt0708-831b
Full Text | PDF
|
|
Errata |
Top |
|
|
|
|
Erratum: Looking forward, looking back p831
doi:10.1038/nbt0708-831c
Full Text | PDF
|
|
|
|
|
Erratum: Is personalized medicine finally arriving? p831
Malorye Allison
doi:10.1038/nbt0708-831d
Full Text | PDF
|
|
Naturejobs |
Top |
|
|
|
| Careers and Recruitment |
|
|
|
|
A walk through the Valley of Death pp833 - 834
Mari Paul
doi:10.1038/nbt0708-833
Expert tips for acquirers and acquirees to get through a difficult post-merger integration.
Full Text | PDF
|
|
|
|
| People |
|
|
|
|
People p836
doi:10.1038/nbt0708-836
Full Text | PDF
|
|
| Top |
|
 |
| Advertisement |
|
Journal of Medical Marketing - recommend to your librarian!
Why wait? Get unlimited desktop access to Journal of Medical Marketing. The Journal provides executives performing a marketing or commercial role at companies producing pharmaceuticals, medical devices or diagnostic equipment for the medical industry with new ideas, the latest intelligence and best practice, making it an indispensable resource. To recommend the Journal to your librarian click here. |
|
|
|
| |
|
|
|
|
|
|
 |
|
|
|
|
Natureevents is a fully searchable, multi-disciplinary database designed to maximise exposure for events organisers. The contents of the Natureevents Directory are now live. The digital version is available here. |
|
|
|
